Related Experiment Video

Updated: May 12, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor

Anna V Miller1, Mark A Hicks, Wataru Nakajima

  • 1Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Plos One
|April 12, 2013
PubMed

Insights

Paclitaxel-induced cell death relies on BAK, not BIM or BAX. This study reveals BAK as a key mediator, suggesting it as a potential therapeutic target for overcoming paclitaxel resistance in cancer.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Paclitaxel (Taxol) induces cancer cell death via the intrinsic pathway, but its precise molecular mechanisms remain unclear.
  • Previous research suggested BIM (BCL-2 Interacting Mediator of cell death) is crucial for paclitaxel-induced apoptosis.
  • The roles of BAK and BAX in paclitaxel-induced apoptosis require further elucidation.

Purpose of the Study:

  • To investigate the specific roles of BIM, BAK, and BAX in paclitaxel-induced apoptosis.
  • To elucidate the molecular mechanisms underlying paclitaxel-induced cell death, focusing on the BCL-2 family proteins.
  • To identify potential therapeutic targets for overcoming paclitaxel resistance.

Main Methods:

  • Utilized bim(-/-) and bak(-/-) mouse embryonic fibroblasts (MEFs) and human breast cancer cells with shRNA-mediated gene silencing.
  • Assessed paclitaxel sensitivity in genetically modified cells and cell lines.
  • Investigated protein degradation pathways using proteasome inhibitor MG132 and Cdk inhibitor roscovitine.
  • Examined protein-protein interactions using co-immunoprecipitation.

Main Results:

  • BIM was dispensable for paclitaxel-induced apoptosis, as demonstrated in bim(-/-) MEFs and human cancer cells.
  • Cells lacking BAK (bak(-/-) MEFs and BAK-downregulated cells) exhibited resistance to paclitaxel, while BAX deficiency did not affect sensitivity.
  • Paclitaxel treatment led to proteasome-dependent degradation of MCL-1, a process inhibited by roscovitine, suggesting Cdk activation's role.
  • BAK activation correlated with MCL-1 degradation and release from a protein complex.

Conclusions:

  • Paclitaxel-induced apoptosis is dependent on BAK but independent of BAX and BIM.
  • MCL-1 degradation, mediated by Cdk activation and proteasome activity, is a critical step in paclitaxel-induced apoptosis.
  • BAK acts as the primary mediator of paclitaxel-induced cell death, presenting a potential target for enhancing treatment efficacy.

More Related Videos

An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth10:38

An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth

Published on: September 22, 2021

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...